Incidence rates and contemporary trends in primary urethral cancer

Wenzel, Mike; Nocera, Luigi; Ruvolo, Claudia Collà; Würnschimmel, Christoph; Tian, Zhe; Shariat, Shahrokh F.; Saad, Fred; Briganti, Alberto; Tilki, Derya; Mandel, Philipp; Becker, Andreas; Kluth, Luis A.; Chun, Felix K.‐H.; Karakiewicz, Pierre I.

doi:10.1007/s10552-021-01416-2

Cited by 21 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…UCs are uncommon in young adults with fewer than 1% of those tumors presenting during the first four decades of life [ 8 ]. Its incidence rates are highest in males, elderly patients, and African Americans [ 9 ]. The most common subtype is the urothelial [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…Its incidence rates are highest in males, elderly patients, and African Americans [ 9 ]. The most common subtype is the urothelial [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…The early presentation of primary UC is commonly a lower urinary obstructive symptom that mimics a stricture of the urethra [ 9 ]. The presence of risk factors or symptoms suggesting cancer like hematuria, or a rapid course of symptoms may suggest a more sinister pathology.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A Primary Urothelial Carcinoma Presenting as a Mid-Bulbar Urethral Stricture in a 30-Year-Old Male

Alghafees

Seyam

Altaweel

et al. 2021

Cureus

View full text Add to dashboard Cite

The bulbar urethra is the most common site of anterior urethral strictures. In this case report, we present a 30-year-old male who was referred to us as a case of mid-bulbar urethral stricture. Urethroplasty was booked and a papillary lesion was found on routine diagnostic cystoscopy. An open biopsy was taken which showed invasive high-grade papillary urothelial carcinoma with squamous differentiation. This case is rare in terms of a young age of incidence, a lack of risk factors, an absence of suspicious symptoms, and a short duration of signs and symptoms. Urologists should consider workup for malignancy even in young patients who present with an idiopathic urethral stricture and a short duration of symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Its incidence rates are highest in males, elderly patients, and African Americans [ 9 ]. The most common subtype is the urothelial [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Primary Urothelial Carcinoma Presenting as a Mid-Bulbar Urethral Stricture in a 30-Year-Old Male

Alghafees

Seyam

Altaweel

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…To access temporal trends in non-SCC and SCC penile cancer, log linear regressions were used to compute estimated annual percent changes (EAPC), as previously described [ 28 , 29 ]. Moreover, Kaplan–Meier plots were fitted to test the effects of non-SCC on CSM across different tumor stages of localized (T 1-2 N 0 M 0 ), locally invasive (T 3-4 N 0 M 0 /T 1-2 N 1-3 M 0 ), and metastatic stages (T 1-4 N 0-3 M 1 ), relative to SCC penile cancer.…”

Section: Methodsmentioning

confidence: 99%

Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma

Wenzel

Siron

Ruvolo

et al. 2021

Cancer Causes Control

Self Cite

View full text Add to dashboard Cite

Purpose To compare Cancer-specific mortality (CSM) in patients with Squamous cell carcinoma (SCC) vs. non-SCC penile cancer, since survival outcomes may differ between histological subtypes. Methods Within the Surveillance, Epidemiology and End Results database (2004–2016), penile cancer patients of all stages were identified. Temporal trend analyses, cumulative incidence and Kaplan–Meier plots, multivariable Cox regression and Fine and Gray competing-risks regression analyses tested for CSM differences between non-SCC vs. SCC penile cancer patients. Results Of 4,120 eligible penile cancer patients, 123 (3%) harbored non-SCC vs. 4,027 (97%) SCC. Of all non-SCC patients, 51 (41%) harbored melanomas, 42 (34%) basal cell carcinomas, 10 (8%) adenocarcinomas, eight (6.5%) skin appendage malignancies, six (5%) epithelial cell neoplasms, two (1.5%) neuroendocrine tumors, two (1.5%) lymphomas, two (1.5%) sarcomas. Stage at presentation differed between non-SCC vs. SCC. In temporal trend analyses, non-SCC diagnoses neither decreased nor increased over time (p > 0.05). After stratification according to localized, locally advanced, and metastatic stage, no CSM differences were observed between non-SCC vs. SCC, with 5-year survival rates of 11 vs 11% (p = 0.9) for localized, 33 vs. 37% (p = 0.4) for locally advanced, and 1-year survival rates of 37 vs. 53% (p = 0.9) for metastatic penile cancer, respectively. After propensity score matching for patient and tumor characteristics and additional multivariable adjustment, no CSM differences between non-SCC vs. SCC were observed. Conclusion Non-SCC penile cancer is rare. Although exceptions exist, on average, non-SCC penile cancer has comparable CSM as SCC penile cancer patients, after stratification for localized, locally invasive, and metastatic disease.

show abstract

“…In all tabulations, differences in rates over time were estimated with estimated annual percent change (EAPC) that relied on log linear methodology, which used the t-test, as an established methodology. 19,20 All tests were two sided with a level of significance set at p < .05 and R software environment for statistical computing and graphics (version 3.4.3) was used for all analyses.…”

Section: Statistical Analysesmentioning

confidence: 99%

Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Recently, an increase in the rates of high-risk prostate cancer (PCa) was reported. We tested whether the rates of and low, intermediate, high and very high-risk PCa changed over time. We also tested whether the number of prostate biopsy cores contributed to changes rates over time.Methods: Within the Surveillance, Epidemiology and End Results (SEER) database (2010)(2011)(2012)(2013)(2014)(2015), annual rates of low, intermediate, high-risk according to traditional National Comprehensive Cancer Network (NCCN) and high versus very high-risk PCa according to Johns Hopkins classification were tabulated without and with adjustment for the number of prostate biopsy cores.Results: In 119,574 eligible prostate cancer patients, the rates of NCCN low, intermediate, and high-risk PCa were, respectively, 29.7%, 47.8%, and 22.5%. Of high-risk patients, 39.6% and 60.4% fulfilled high and very high-risk criteria. Without adjustment for number of prostate biopsy cores, the estimated annual percentage changes (EAPC) for low, intermediate, high and very high-risk were respectively −5.5% (32.4%-24.9%, p < .01), +0.5% (47.6%-48.4%, p = .09), +4.1% (8.2%-9.9%, p < .01), and +8.9% (11.8%-16.9%, p < .01), between 2010 and 2015. After adjustment for number of prostate biopsy cores, differences in rates over time disappeared and ranged from 29.8%-29.7% for low risk, 47.9%-47.9% for intermediate risk, 8.9%-9.0% for high-risk, and 13.6%-13.6% for very high-risk PCa (all p > .05). Conclusions:The rates of high and very high-risk PCa are strongly associated with the number of prostate biopsy cores, that in turn may be driven by broader use magnetic resonance imaging (MRI).

show abstract

Incidence rates and contemporary trends in primary urethral cancer

Cited by 21 publications

References 18 publications

A Primary Urothelial Carcinoma Presenting as a Mid-Bulbar Urethral Stricture in a 30-Year-Old Male

A Primary Urothelial Carcinoma Presenting as a Mid-Bulbar Urethral Stricture in a 30-Year-Old Male

Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma

Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores

Contact Info

Product

Resources

About